Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell linesKeisuke Taniguchi(Yakult Honsha (Japan)), Akira Asai(Osaka Medical and Pharmaceutical University)Research SquareDecember 23, 202010.21203/rs.3.rs-123999/v1Cited by 1SaveCiteExport RISWatch citationsRelated PapersEfficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines|Scientific Reports|2021|12CD34+CD31+ immature myeloid cells (IMC) as an inhibitor cell on the production of antimicrobial peptide: II. Glycyrrhizin inhibits IMC suppressor cell activities (89.27)|The Journal of Immunology|2010|0